Kirom Bukhoroi

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed against Kiromic BioPharma, Inc. (KRBP) and Encourages Investors with Significant Losses to Contact the Firm

Retrieved on: 
Friday, August 19, 2022 - 2:15pm

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. (Kiromic) ( NASDAQ: KRBP ).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Kiromic BioPharma, Inc. (Kiromic) ( NASDAQ: KRBP ).
  • As a result of Kiromics materially misleading statements and omissions to the public, Kiromic investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Kiromic investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Kiromic BioPharma, Inc.

Retrieved on: 
Thursday, August 18, 2022 - 10:27pm

Kessler Topaz Meltzer & Check, LLP encourages Kiromic investors who have suffered significant losses to contact the firm directly to acquire more information.

Key Points: 
  • Kessler Topaz Meltzer & Check, LLP encourages Kiromic investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.
  • For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .

KRBP ALERT: Hagens Berman, National Trial Attorneys, Encourages Investors in Kiromic BioPharma (KRBP) with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Retrieved on: 
Tuesday, August 16, 2022 - 9:48pm

SAN FRANCISCO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now .
  • Were focused on investors losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Kiromic and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

ROSEN, A TOP RANKED LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Retrieved on: 
Tuesday, August 16, 2022 - 7:53pm

WHAT TO DO NEXT: To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kiromic BioPharma class action, go to https://rosenlegal.com/submit-form/?case_id=8051 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Carvana, and Kiromic and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, August 16, 2022 - 2:00am

Coinbase provides financial infrastructure and technology products and services for the cryptocurrency economy (or cryptoeconomy) in the U.S. and internationally.

Key Points: 
  • Coinbase provides financial infrastructure and technology products and services for the cryptocurrency economy (or cryptoeconomy) in the U.S. and internationally.
  • Following this disclosure, the price of Coinbases Class A common stock fell $19.27 per share, or 26.4%, to close at $53.72 per share on May 11, 2022.
  • For more information on the Kiromic class action go to: https://bespc.com/cases/KRBP
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Kiromic Biopharma, Inc. Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)

Retrieved on: 
Friday, August 12, 2022 - 5:05pm

Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.

Key Points: 
  • Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.
  • If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here .
  • Rather than disclosing this information, Kiromic represented that clinical testing was expected to proceed in the third quarter of 2021.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Carvana and Kiromic and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, August 11, 2022 - 2:00am

On June 24, 2022, Barrons published an article entitled Carvana Sought to Disrupt Auto Sales.

Key Points: 
  • On June 24, 2022, Barrons published an article entitled Carvana Sought to Disrupt Auto Sales.
  • On this news, Carvanas share price fell approximately 21% over the next two trading days, damaging investors.
  • For more information on the Kiromic class action go to: https://bespc.com/cases/KRBP
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

EQUITY ALERT: Rosen Law Firm Encourages Kiromic BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – KRBP

Retrieved on: 
Wednesday, August 10, 2022 - 10:51pm

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.

Key Points: 
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)

Retrieved on: 
Wednesday, August 10, 2022 - 3:49am

Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.

Key Points: 
  • Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.
  • If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here .
  • Rather than disclosing this information, Kiromic represented that clinical testing was expected to proceed in the third quarter of 2021.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

KIROMIC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kiromic BioPharma, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, August 10, 2022 - 2:00am

Investors have until October 4, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until October 4, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • The Offering Documents failed to disclose this information, instead representing that clinical testing was expected to proceed in the third quarter of 2021.
  • Clinical testing did not proceed in the third quarter of 2021, nor was it likely given the FDAs imposition of a clinical hold.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.